<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317028</url>
  </required_header>
  <id_info>
    <org_study_id>CS02-001</org_study_id>
    <nct_id>NCT03317028</nct_id>
    <nct_alias>NCT03308695</nct_alias>
  </id_info>
  <brief_title>CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Laboratories, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to compare the efficacy and safety of 3 doses CS02 Tablet in
      combination with a stable dose of metformin monotherapy against CS02 PTM (placebo) Tablet in
      combination with a stable dose of metformin monotherapy over a 12 weeks treatment period in
      subjects with type 2 diabetes mellitus with inadequate glycemic control on metformin alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The HbA1c treatment effect among CS02 groups and the Placebo group</measure>
    <time_frame>12 weeks</time_frame>
    <description>To assess 208 evaluable subject of the change in HbA1c from baseline to end of treatment among CS02 groups and CS02 placebo to match group will be compared with the analysis of covariance model including baseline HbA1c as covariate, and treatment groups and regions as fixed effects.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>T2DM With Inadequate Glycemic Control</condition>
  <arm_group>
    <arm_group_label>high dose of CS02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 450mg of CS02 combined with a stable dose of metformin monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>middle dose of CS02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 300mg of CS02 combined with a stable dose of metformin monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose of CS02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 150mg of CS02 combined with a stable dose of metformin monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo combined with a stable dose of metformin monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS02 tablet and placebo tablet</intervention_name>
    <description>Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.</description>
    <arm_group_label>high dose of CS02</arm_group_label>
    <arm_group_label>middle dose of CS02</arm_group_label>
    <arm_group_label>low dose of CS02</arm_group_label>
    <arm_group_label>placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with diagnosis of type 2 diabetes mellitus at least 12 weeks prior to Visit
             1;

          2. Outpatient, either male or female, aged 20 years or older from Taiwan and aged 18
             years or older from united States; all subjects are ≤75 years old;

          3. Subjects with a stable diet and exercise program for ≧8 weeks prior to Visit 1;

          4. Subjects with HbA1c value ≧7.0% and ≦10.0% at Visit 1;

          5. Subjects with a stable dose of metformin monotherapy of ≥1500 mg/day at least 12 weeks
             before randomization (Visit 2);

          6. Body mass index (BMI) between 20.0 and 45.0 kg/m2at Visit 1;

          7. Subjects have adequate liver function, defined as serum total bilirubin≤1.5 times the
             upper limit of normal (uLN); aspartate aminotransferase (AST) and alanine
             aminotransferase (ALT)≤3 times uLN at Visit 1;

          8. Subjects have estimated glomerular filtration rate (e-GFR)* values of≧ 45ml/min/1.73m2
             at Visit1;

          9. Female subjects of childbearing potential， defined as women≤ 55 years old or history
             of amenorrhea ≤ 12 months prior to the study entry or not surgically sterile, must
             have a negative pregnancy test at Visit 1 and agree to use a highly effective
             contraceptive method during the study period;

         10. Willing to provide a written informed consent form;

         11. Willingness and ability to comply with treatment plans, scheduled visits, required
             laboratory tests, and other study procedures;

        Exclusion Criteria:

          1. Subjects with type 1 diabetes mellitus, secondary diabetes mellitus, or gestational
             diabetes;

          2. Subjects with acute or chronic metabolic acidosis, including diabetic ketoacidosis,
             with or without coma at Visit 1 or Visit 2;

          3. Subjects with hypotension (average systolic pressure &lt; 90 mm Hg*) at Visit 1 or Visit
             2;

          4. Subjects with cardiogenic shock within 8 weeks prior to Visit 1;

          5. Subjects with sick sinus syndrome, second- or third-degree atrioventricular block (AV
             block);

          6. Subjects with atrial flutter or atrial fibrillation and an accessory bypass tract
             (e.g., Wolff-Parkinson-White, Lown-Ganong-Levine syndromes);

          7. Subjects with recurrence or history of transient ischemic attack or coronary artery
             bypass surgery;

          8. Subjects with history of cerebrovascular attack, myocardial infarction, serious
             cardiac disease (New York Heart Association NYHA Class III to IV), left ventricular
             ejection fraction≦40% within 12 weeks prior to Visit 1, or those with cardiovascular
             disease or cerebrovascular disease that may affect the administration of IP tablets
             (CS02) or its safety assessment in the opinion of the investigator or
             sub-investigator;

          9. Female subjects who are nursing or pregnant during the study period;

         10. Subjects are on a weight loss program and not in the maintenance phase or have started
             a weight loss medication including but not limited to Orlistat, Phentermine, Osymia,
             or Belviq or have undergone bariatric surgery within 8 weeks prior to Visit 1 or any
             type of surgery planned during the study;

         11. Subjects with a clinically severe gastrointestinal disorder including diabetic
             gastroparesis; irritable bowel disease; recurrent episodes of nausea, vomiting,
             diarrhea and abdominal pain within 12 weeks prior to Visit 1;

         12. Subjects have a history or current of substance or alcohol abuse;

         13. Subjects have uncontrolled psychiatric disorder(s);

         14. Subjects are less than 5 years free of malignancy (except for cured basal cell
             carcinoma of skin and cured carcinoma in situ of the uterine cervix);

         15. Subjects have participated in another clinical trial within the last 12 weeks prior to
             Visit 1;

         16. Subjects who are considered unreliable as to medication compliance or adherence to
             scheduled appointments, or inappropriate for inclusion per investigators, judgments;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Shane</last_name>
    <phone>+886-2-2655 8680</phone>
    <phone_ext>621</phone_ext>
    <email>eric_shane@centerlab.comtw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosen Jeffrey, MD</last_name>
      <phone>305-445-5637</phone>
      <email>jrosen@crsouthflorida.com</email>
    </contact>
    <investigator>
      <last_name>Rosen Jeffrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Community Research of South Florida</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carpio Jose, MD</last_name>
      <phone>305-441-6611</phone>
      <email>jcarpio@thecommunityresearch.com</email>
    </contact>
    <investigator>
      <last_name>Carpio Jose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Hsun Chu, MD</last_name>
      <phone>+886-7-3422-121</phone>
      <phone_ext>8089</phone_ext>
      <email>chchu@vghks.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Chih-Hsun Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans general Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang-Hsun Hsieh, MD</last_name>
      <phone>+886-2-8792-7182</phone>
      <email>10324@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chang-Hsun Hsieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital_Linkou</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

